iRepertoire, Inc.

iRepertoire was the first to develop and commercialize immune repertoire sequencing technology and products.

iRepertoire uses immune repertoire sequencing technology to access the body’s immunological memory, or “logbook” of all past infection and disease. Sequencing the immune repertoire can yield insights into the nature of the body’s immune response to disease and infection. The future market for iRepertoire will be in clinical and research applications that require immune assessment such as drug treatment monitoring, identification of minimal residual disease (MRD), immune monitoring after stem cell transplantation, vaccine studies, and biomarker development.

iRepertoire provides primer kits and amplification to sequencing services to examine the TCR and BCR immune diversity in both humans and mice. iRepertoire also offers access to its proprietary repertoire analysis tools with the purchase of its regent systems.

iRepertoire’s reagent systems allow researchers to easily and inexpensively generate their own Next Generation Sequencing libraries in the convenience of their laboratory and analyze their data with the iRepertoire’s proprietary software pipeline at no additional cost.This year, iRepertoire has launched automated immune repertoire amplification and extraction on their sister company’s iC-processor (iCubate, Inc.).

iRepertoire is proud to be a part of the non-profit initiative R10K, or Repertoire 10,000, with the HudsonAlpha Institute for Biotechnology, which aims to study the immune repertoire of 100 different diseases. The company has developed two key indices to describe the immune repertoire, i.e., the diversity index and the sharing index. These indices allow iRepertoire to identify disease specific signatures for diagnosis, prognosis, and treatment guidance.